Steven Morgan, Ph.D., Jamie Daw, M.Sc., and Paige Thomson
S. Morgan, J. Daw, and P. Thomson, "International Best Practices for Negotiating 'Reimbursement Contracts' with Price Rebates from Pharmaceutical Companies," Health Affairs, April 2013 32(4):771–77.
In a growing number of countries, governments are negotiating rebate agreements with pharmaceutical firms so that health insurers can avoid paying the full list price for prescription drugs. These "reimbursement contracts" can present challenges, however. Policymakers should set clear and consistent processes for contract negotiations and monitor how this approach affects differences among drug prices within and across nations.
Reimbursement contracts have been common in the United States since 1980, and their prevalence is growing in other wealthy nations. The trend appears to be driven by pharmaceutical manufacturers, which prefer confidential rebate arrangements to making price discounts available to all payers globally. In a Commonwealth Fund–supported study, Steven Morgan, a 2001–02 Commonwealth Fund Canadian Associate Harkness Fellow, and colleagues sought to determine best practices for reimbursement contract negotiation based on the experiences of health care payers in the U.S. and in eight other industrialized countries.
In the U.S., large insurers may have sufficient bargaining power to garner the best available rebates. Some small purchasers, however, are unable to secure large discounts, and patients without a drug benefit plan are often unable to obtain any discount at all. These issues could also replicate globally: specifically, countries with little buying power (like small U.S. insurance plans) or countries with major gaps in health insurance coverage (like uninsured Americans) may be left paying the highest drug prices under this new global pricing paradigm. In the U.S., policymakers should consider the impact of this price discrimination on the uninsured and underinsured, the authors say. At the same time, with more Americans eligible for health insurance coverage under the Affordable Care Act and with the gradual closing of Medicare’s "doughnut hole" in drug coverage, fewer patients will be exposed to the full list prices for drugs in the future.
Researchers interviewed policymakers involved in health coverage decisions in nine countries: Australia, Austria, Canada, Germany, Italy, the Netherlands, New Zealand, the United Kingdom, and the United States. Questions explored the reimbursement contracts in use in each nation, policymakers’ motivations for or rationale against using them, challenges faced, and best practices.
Reimbursement contracts present opportunities and challenges to policymakers as they seek to negotiate prices that reflect the true value of new drugs to society.